Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Chang eun Jang"'
Autor:
Chang eun Jang, Mi Sook Jung, Eun Hee Sohn, Mijung Kim, Hwa-Seung Yoo, Kyeore Bae, Je Ryong Kim, Jin Sun Lee
Publikováno v:
Trials, Vol 19, Iss 1, Pp 1-9 (2018)
Abstract Background Chemotherapy-induced peripheral neuropathy (CIPN) is a progressive, enduring, and sometimes irreversible neurotoxic symptom that occurs in 30–40% of chemotherapy-treated cancer patients. CIPN negatively affects both the patient
Externí odkaz:
https://doaj.org/article/cbf6c4d47a6d456eb4fd209815f6b87d
Autor:
Chang-Eun Jang
Publikováno v:
The Journal for the Studies of Korean History. 89:323-356
Autor:
Chang-Eun Jang, Je-Ryoung Kim
Publikováno v:
Korean Journal of Clinical Oncology, Vol 11, Iss 2, Pp 106-113 (2015)
Purpose: The aim of this study is to evaluate the prognostic factors of the group who received neoadjuvant chemotherapy with a taxane-anthracycline combination regimen. Methods: We retrospectively analyzed for locally advanced breast cancer patients
Externí odkaz:
https://doaj.org/article/382de8773e034002bd58d0cec0388ab2
Autor:
Chang-eun Jang
Publikováno v:
A Laboratory of Korean Studies. 55:389-429
Autor:
Chang-eun Jang
Publikováno v:
Sogang Journal of Early Korean History. 36:11-72
Autor:
Chang-eun Jang
Publikováno v:
Sogang Journal of Early Korean History. 33:281-331
Autor:
Chang eun Jang
Publikováno v:
탐라문화. :87-121
Autor:
Chang-eun Jang
Publikováno v:
The Journal for the Studies of Korean History. 67:107-141
554년 관산성 전투를 주도한 여창[위덕왕, 554~598]은 즉위 후 한동안 패전의 후유증을 겪었다. 위덕왕이 통치활동을 재개한 것은 재위 14년(567) 부터였다. 이때부터 중국 남북조의 국가들과 대
Autor:
Chang-eun Jang
Publikováno v:
Sogang Journal of Early Korean History. 21:45-86
Autor:
Jin Sun Lee, Mi Sook Jung, Je Ryong Kim, Hwa-Seung Yoo, Mijung Kim, Eun Hee Sohn, Kyeore Bae, Chang eun Jang
Publikováno v:
Trials
Trials, Vol 19, Iss 1, Pp 1-9 (2018)
Trials, Vol 19, Iss 1, Pp 1-9 (2018)
Background Chemotherapy-induced peripheral neuropathy (CIPN) is a progressive, enduring, and sometimes irreversible neurotoxic symptom that occurs in 30–40% of chemotherapy-treated cancer patients. CIPN negatively affects both the patient’s abili